All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

elotuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5072	915296-00-3

Description:

Molecule	Description
Synonyms: elotuzumab empliciti BMS-901608 HuLuc63	a humanized monoclonal antibody that selectively targets glycoproteins expressed on myeloma cells Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 11, 2016	EMA	Bristol-Myers Squibb
Nov. 30, 2015	FDA	BRISTOL MYERS SQUIBB
Sept. 28, 2016	PMDA	Bristol-Myers Squibb

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	213.10	24.88	93	2732	82028	63404169
Plasma cell myeloma	87.45	24.88	39	2786	35866	63450331
Pneumonia	69.71	24.88	93	2732	456674	63029523
Platelet count decreased	64.48	24.88	48	2777	116074	63370123
Cytomegalovirus infection	51.75	24.88	23	2802	20929	63465268
Death	50.60	24.88	72	2753	374309	63111888
Pyrexia	48.81	24.88	80	2745	470398	63015799
Lymphocyte count decreased	46.57	24.88	24	2801	30233	63455964
Febrile infection	44.83	24.88	11	2814	1546	63484651
Neutrophil count decreased	44.60	24.88	29	2796	56377	63429820
Pneumococcal sepsis	42.04	24.88	9	2816	691	63485506
Neutropenia	36.78	24.88	42	2783	174963	63311234
Pneumonia pneumococcal	36.31	24.88	10	2815	2205	63483992
Diarrhoea	34.93	24.88	89	2736	715277	62770920
Thrombocytopenia	31.27	24.88	36	2789	151121	63335076
Febrile neutropenia	31.11	24.88	32	2793	118417	63367780
Neuropathy peripheral	30.38	24.88	31	2794	113636	63372561
Anaemia	29.09	24.88	49	2776	293381	63192816
Sepsis	27.60	24.88	34	2791	153089	63333108
Meningitis pneumococcal	25.06	24.88	5	2820	271	63485926

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	152.75	26.89	102	3591	87944	34865294
Pneumonia	107.62	26.89	159	3534	362468	34590770
Plasma cell myeloma	75.78	26.89	50	3643	41987	34911251
Febrile infection	43.57	26.89	14	3679	2197	34951041
Platelet count decreased	41.74	26.89	57	3636	119660	34833578
Keratopathy	39.97	26.89	10	3683	635	34952603
Sepsis	37.84	26.89	65	3628	166496	34786742
Campylobacter gastroenteritis	36.88	26.89	10	3683	871	34952367
Squamous cell carcinoma of skin	35.49	26.89	19	3674	10862	34942376
Neuropathy peripheral	32.61	26.89	42	3651	83221	34870017
Pneumonia respiratory syncytial viral	31.83	26.89	9	3684	914	34952324
Visceral leishmaniasis	30.62	26.89	8	3685	604	34952634
Pneumonia mycoplasmal	30.02	26.89	8	3685	652	34952586
Neutropenia	28.99	26.89	56	3637	156722	34796516
White blood cell count decreased	28.15	26.89	42	3651	95403	34857835
Influenza A virus test positive	27.11	26.89	6	3687	223	34953015
Respirovirus test positive	26.99	26.89	5	3688	74	34953164

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	324.32	27.00	167	5375	135823	79603023
Pneumonia	167.16	27.00	216	5326	660030	79078816
Platelet count decreased	102.34	27.00	94	5448	194570	79544276
Plasma cell myeloma	97.37	27.00	55	5487	53204	79685642
Pyrexia	71.67	27.00	150	5392	678559	79060287
Neutrophil count decreased	68.95	27.00	55	5487	93904	79644942
Sepsis	65.79	27.00	87	5455	269341	79469505
Neutropenia	59.85	27.00	86	5456	287624	79451222
Febrile infection	56.22	27.00	17	5525	3329	79735517
Lymphocyte count decreased	55.97	27.00	37	5505	47252	79691594
Cytomegalovirus infection	52.01	27.00	34	5508	42610	79696236
White blood cell count decreased	50.91	27.00	64	5478	188224	79550622
Anaemia	49.91	27.00	101	5441	444914	79293932
Death	48.16	27.00	115	5427	566399	79172447
Febrile neutropenia	46.46	27.00	68	5474	230931	79507915
Plasma cell myeloma recurrent	41.84	27.00	15	5527	4986	79733860
Neuropathy peripheral	39.72	27.00	49	5493	141256	79597590
Keratopathy	38.01	27.00	10	5532	1184	79737662
Septic shock	36.81	27.00	44	5498	122757	79616089
Campylobacter gastroenteritis	36.68	27.00	10	5532	1355	79737491
Thrombocytopenia	34.28	27.00	64	5478	265195	79473651
Atrial fibrillation	33.76	27.00	54	5488	197832	79541014
Squamous cell carcinoma of skin	32.59	27.00	17	5525	14016	79724830
COVID-19	28.22	27.00	44	5498	157630	79581216
Pulmonary embolism	28.12	27.00	46	5496	171608	79567238
Bacteraemia	27.93	27.00	21	5521	32803	79706043

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FX08	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates
FDA CS	M0001357	Antibodies, Monoclonal
MeSH PA	D000970	Antineoplastic Agents
FDA MoA	N0000192337	SLAMF7-directed Antibody Interactions
FDA EPC	N0000192338	SLAMF7-directed Immunostimulatory Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Multiple myeloma	indication	109989006	DOID:9538
Relapse multiple myeloma	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
SLAM family member 7	Membrane receptor	Q9NQ25	SLAF7_HUMAN	ANTIBODY BINDING	Kd	8.05		IUPHAR	DRUG LABEL

External reference:

ID	Source
1351PE5UGS	UNII
4035187	VANDF
C1832049	UMLSCUI
CHEMBL1743010	ChEMBL_ID
DB06317	DRUGBANK_ID
9074	INN_ID
C546027	MESH_SUPPLEMENTAL_RECORD_UI
8361	IUPHAR_LIGAND_ID
1726104	RXNORM
237251	MMSL
31305	MMSL
d08403	MMSL
016608	NDDF
715660001	SNOMEDCT_US
781350003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2291	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAVENOUS	BLA	26 sections
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2291	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAVENOUS	BLA	26 sections
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2291	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAVENOUS	BLA	26 sections
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-4522	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	400 mg	INTRAVENOUS	BLA	26 sections
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-4522	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	400 mg	INTRAVENOUS	BLA	26 sections
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-4522	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	400 mg	INTRAVENOUS	BLA	26 sections